{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001340","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.213907+00:00","generated_at":"2026-05-15T19:48:03.291909+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos reports Q4/FY2025 net loss of $19.9M and $24.2M; cash $77.8M; Phase 2 HBV study progressing","bullets":["Net loss Q4 2025 $19.9M ($1.91/sh) vs $82.2M ($13.08/sh) in Q4 2024; FY2025 net loss $24.2M ($2.45/sh) vs $131.2M ($20.94/sh) in FY2024.","Cash, cash equivalents and investments $77.8M as of Dec 31, 2025, up from $56.9M; funding expected into Q3 2026.","Phase 2 B-SUPREME study of pevifoscorvir sodium completed 60 HBeAg- enrollment; topline data expected 2027.","ALG-170675 ASO advanced to IND-enabling studies with partner Amoytop; Amoytop funds China development.","James Hassard appointed EVP, Chief Commercial Officer; ALG-055009 preclinical data showed synergistic weight loss with incretins."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001340","json":"https://secwatch.observer/filing/0001171843-26-001340.json","markdown":"https://secwatch.observer/filing/0001171843-26-001340.md","text":"https://secwatch.observer/filing/0001171843-26-001340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184326001340/0001171843-26-001340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184326001340/f8k_030426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:48:03.291909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}